Literature DB >> 14514520

Delivery of CFTR by adenoviral vector to cystic fibrosis mouse lung in a model of chronic Pseudomonas aeruginosa lung infection.

Anna M Van Heeckeren1, Abraham Scaria, Mark D Schluchter, Thomas W Ferkol, Samuel Wadsworth, Pamela B Davis.   

Abstract

In cystic fibrosis (CF) there is an excessive inflammatory response to lung infections with Pseudomonas aeruginosa, which causes significant morbidity and mortality. Mice deficient in the cystic fibrosis conductance transmembrane regulator homolog (Cftr) have exaggerated production of proinflammatory cytokines in epithelial lining fluid and increased mortality in response to chronic bronchopulmonary infection with mucoid P. aeruginosa, compared with infected wild-type littermates. Whether delivery of CFTR to CF airways by an adenoviral vector (Ad2/CFTR-16) decreases cytokine production and mortality in response to chronic bronchopulmonary infection with mucoid P. aeruginosa was tested. CF mice [stock Cftrtm1Unc-TgN(FABPCFTR)#Jaw] were anesthetized with isoflurane and inoculated intranasally with either Ad2/CFTR-16, diluent (sucrose), or empty vector (Ad2/EV). Two weeks later, mice were anesthetized with 2.5% Avertin and inoculated transtracheally with P. aeruginosa-laden agarose beads (PA M57-15). The cumulative 10-day survival of mice pretreated with Ad2/CFTR-16 was significantly higher compared with mice pretreated with sucrose but not significantly higher than mice pretreated with Ad2/EV. After adjusting for differences in experiment, we found weight loss at 3 days for mice treated with Ad2/CFTR-16 to be significantly less than for the sucrose- or Ad2/EV-treated groups. However, cytokine responses were similar in all groups 3 days after infection. In conclusion, the observed survival advantage of adenoviral delivery of CFTR to the CF lung may be due either to CFTR expression or possibly to proinflammatory effects of the adenoviral vector, or both.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14514520     DOI: 10.1152/ajplung.00227.2003

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  9 in total

1.  Partial Restoration of CFTR Function in cftr-Null Mice following Targeted Cell Replacement Therapy.

Authors:  Pascal Duchesneau; Rickvinder Besla; Mathieu F Derouet; Li Guo; Golnaz Karoubi; Amanda Silberberg; Amy P Wong; Thomas K Waddell
Journal:  Mol Ther       Date:  2017-02-08       Impact factor: 11.454

2.  Response to acute lung infection with mucoid Pseudomonas aeruginosa in cystic fibrosis mice.

Authors:  Anna M van Heeckeren; Mark D Schluchter; Wei Xue; Pamela B Davis
Journal:  Am J Respir Crit Care Med       Date:  2005-11-04       Impact factor: 21.405

3.  N-acetylcysteine enhances cystic fibrosis sputum penetration and airway gene transfer by highly compacted DNA nanoparticles.

Authors:  Jung Soo Suk; Nicholas J Boylan; Kanika Trehan; Benjamin C Tang; Craig S Schneider; Jung-Ming G Lin; Michael P Boyle; Pamela L Zeitlin; Samuel K Lai; Mark J Cooper; Justin Hanes
Journal:  Mol Ther       Date:  2011-08-09       Impact factor: 11.454

4.  Critical modifier role of membrane-cystic fibrosis transmembrane conductance regulator-dependent ceramide signaling in lung injury and emphysema.

Authors:  Manish Bodas; Taehong Min; Steven Mazur; Neeraj Vij
Journal:  J Immunol       Date:  2010-12-06       Impact factor: 5.422

5.  Species-specific differences in mouse and human airway epithelial biology of recombinant adeno-associated virus transduction.

Authors:  Xiaoming Liu; Ziying Yan; Meihui Luo; John F Engelhardt
Journal:  Am J Respir Cell Mol Biol       Date:  2005-09-29       Impact factor: 6.914

6.  Nutritional effects on host response to lung infections with mucoid Pseudomonas aeruginosa in mice.

Authors:  Anna M van Heeckeren; Mark Schluchter; Lintong Xue; Juan Alvarez; Steven Freedman; Judith St George; Pamela B Davis
Journal:  Infect Immun       Date:  2004-03       Impact factor: 3.441

7.  HE3286, an oral synthetic steroid, treats lung inflammation in mice without immune suppression.

Authors:  Douglas Conrad; Angela Wang; Raymond Pieters; Ferdinando Nicoletti; Katia Mangano; Anna M van Heeckeren; Steven K White; James M Frincke; Christopher L Reading; Dwight Stickney; Dominick L Auci
Journal:  J Inflamm (Lond)       Date:  2010-10-30       Impact factor: 4.981

8.  Development of PEGylated PLGA nanoparticle for controlled and sustained drug delivery in cystic fibrosis.

Authors:  Neeraj Vij; Taehong Min; Rhul Marasigan; Christopher N Belcher; Steven Mazur; Hong Ding; Ken-Tye Yong; Indrajit Roy
Journal:  J Nanobiotechnology       Date:  2010-09-24       Impact factor: 10.435

Review 9.  Cystic Fibrosis Gene Therapy: Looking Back, Looking Forward.

Authors:  Ashley L Cooney; Paul B McCray; Patrick L Sinn
Journal:  Genes (Basel)       Date:  2018-11-07       Impact factor: 4.096

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.